GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide that releases growth hormone by acting on the pituitary through a receptor distinct from the GHRH receptor. It was first described by Bowers and colleagues in 1984 as "a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone," and even then it was clear it worked through a mechanism separate from classical hypothalamic GHRH [1].

About this page. This is a reference monograph that neutrally summarises published laboratory and clinical research. GHRP-6 is a research-use-only (RUO) compound: it has no approved indication in any jurisdiction and is not a medicine. There are no doses, protocols, or human-use instructions here. The sections describe what the published studies did, in which species, and what exactly they measured. Dosing as it was described in studies is kept in separate reference documents (see GHRP-6 dosing and the general peptide dosage chart).

Mechanism: the ghrelin receptor, not GHRH

Growth-hormone secretion from the somatotroph of the anterior pituitary is governed by at least three inputs: stimulatory GHRH, inhibitory somatostatin, and ghrelin, which acts through a separate receptor and modulates the first two. It is the interplay of these inputs that produces the pulsatile secretion pattern characteristic of every mammal studied [9]. GHRP-6 plugs into this system not through the GHRH receptor but through the ghrelin receptor.

GHS-R1a: the receptor found "backwards"

The synthetic growth-hormone-releasing peptides were discovered before anyone knew what they bound to. In 1996 Howard and colleagues cloned the receptor these compounds act on (a G-protein-coupled receptor in the pituitary and hypothalamus, distinct from the GHRH receptor) and showed that it functions in growth-hormone release [2]. It signals through Gq/11 and the phospholipase C / IP3 / calcium cascade, a different second messenger from the GHRH receptor's cAMP. At that point it was an orphan receptor: a lock with a synthetic key and no known natural one.

The natural ligand turned up three years later. Kojima and colleagues isolated ghrelin from the stomach, a 28-amino-acid peptide carrying an unusual n-octanoyl modification on Ser3 without which it does not activate the receptor [3]. So GHS-R1a is really the ghrelin receptor, and GHRP-6 is a synthetic agonist that simply got there first.

Structure and molecular design

GHRP-6 is a six-residue peptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 [1]. Two design features stand out. The D-amino acids (D-Trp at position 2, D-Phe at position 5) are non-natural. That stereochemistry is a standard way to blunt recognition by proteases that evolved against L-peptides. The C-terminal amide removes the free carboxylate that carboxypeptidases would attack. Even so, GHRP-6 remains a short-acting molecule: in the published work its action is measured in minutes, not hours. The class as a whole (synthetic secretagogues acting at GHS-R1a) was reviewed in detail by Smith and colleagues as peptidomimetic regulators of a separate, GHRH-independent branch of growth-hormone control [6].

The appetite component

Because GHRP-6 activates the ghrelin receptor, it engages a pathway that is about more than growth hormone. Ghrelin's other well-documented role is orexigenic. Wren and colleagues showed that central administration of ghrelin stimulates food intake in rats, over and above growth-hormone release [7], establishing GHS-R1a as a node where the somatotropic and appetite systems intersect. The human appetite data for GHRP-6 specifically deserve a careful statement: see the section below.

Synergy with GHRH

The most informative feature of GHRP-6 appears in combination with GHRH. Because GHRP-6 and GHRH act through separate receptors and separate second-messenger systems (calcium versus cAMP), their effects do not simply add. Bowers and colleagues documented that GHRP and GHRH act synergistically: co-administration produces a response substantially greater than the sum of each alone [4]. Two orthosteric agonists of the same site cannot be synergistic: a more-than-additive response is evidence that two signals converge on one cell by independent routes. The same authors explicitly ruled out the obvious explanations: the synergy reduced neither to suppression of somatostatin nor to stimulation of endogenous GHRH, and the exact mechanism was left open [4].

Research evidence: what is preclinical, what is human

The gap between what has been shown in animals and cells and what has been shown in humans is large here, so let us separate them plainly.

Preclinical data (animal and in vitro)

The mechanistic core of GHRP-6 is mostly rodent and cell-model work. The hexapeptide's primary pituitary activity was established in vitro and in vivo in animals [1]. The cloning and functional characterisation of GHS-R1a were done in pituitary and hypothalamic tissue and cell systems [2]; the identification of ghrelin as the natural ligand came from rat stomach [3]; the orexigenic effect was in rats [7]; and the characterisation of GHRP/GHRH synergy leans heavily on animal models [4]. Cross-species differences in this axis are real, so these results do not transfer to humans directly.

Human data

A direct human study in this class does exist, and it is worth stating precisely. Bowers and colleagues administered GHRP to healthy men and reported that the peptide stimulates growth-hormone release and acts synergistically with GHRH. That is, the synergy shown in animals reproduced in humans too [5]. This is early, small-scale physiology: it characterises the hormonal response (a biomarker, a growth-hormone pulse), not a clinical outcome, and is not designed to assess long-term safety. On appetite, the honest framing is this: the strongest human food-intake data in the class are for GHRP-2, not GHRP-6. Laferrère and colleagues gave GHRP-2 to healthy men and recorded increased food intake [8]. Extending that to GHRP-6 is a receptor-level inference (both are GHS-R1a agonists), not a direct GHRP-6 finding.

What is absent

  • No approved indication. GHRP-6 is not a registered medicine anywhere; it is a laboratory reagent. There is no clinical development that reached registration.
  • The human dataset is small and short. The available human work is early-phase, in small groups of healthy adults, with short follow-up [5]. It characterises a hormonal response; it does not establish efficacy or long-term safety.
  • Raising a hormone is not the same as an outcome. Increased growth hormone and IGF-1 are biomarkers; studies that measure them report exactly that and demonstrate no downstream clinical benefit.
  • The literature is largely old. Much of the foundational work dates to the 1980s and 1990s; little has been added since, which is itself informative.

Pulsatility and the axis

Growth hormone is not secreted at a steady level but in discrete bursts; the amplitude, frequency, and troughs between them are a regulated feature of the axis, not noise [9]. For a secretagogue this is important context: receptor stimulation on its own does not abolish the oscillating inhibitory somatostatin input that gates the somatotroph. Because of its short action, GHRP-6's stimulus is pulsatile by nature, unlike multi-day GHRH analogues, for which the question of preserving pulsatility is far sharper. A detailed review of the neuroendocrine regulation of growth-hormone secretion is given by Steyn and colleagues [9].

Dosing context

This page carries no protocols or doses. The quantitative parameters mentioned in the primary studies are stated there in their own experimental context and are not recommendations. Reference material on how dosing was described in studies is kept in separate documents: GHRP-6 dosing and the general peptide dosage chart.

Research status and handling

GHRP-6 ships as a lyophilised powder, a stability decision, not a packaging preference: peptides in solution degrade far faster than in the dry state. Solvent choice depends on the task: in vitro and cell-culture work typically uses sterile water, buffered saline (PBS), or, for peptides that need it, dilute acetic acid, with preservative-free options preferred wherever cells are involved. Bacteriostatic water is a different thing: a solvent with benzyl alcohol as a preservative; our monograph on bacteriostatic water covers where that difference matters. A reconstituted solution is kept refrigerated and protected from light, and stability windows should be treated as indicative, not as validated specifications. Specifications and analytics for our reference material are on the GHRP-6 product page; every lot we ship carries independent purity and identity verification. For compounds like these, provenance and analytics are the whole question, not the label.

Longeva supplies these materials for research use only. We provide no dosing protocols or administration guidance, and nothing on this page should be read as medical advice.